Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Post by retiredcopon May 24, 2020 9:55am
241 Views
Post# 31066105

Our Success is developing the needs for Canada

Our Success is developing the needs for Canada Focus locally/ in Canada,, we have great scientists that can come up with terrific porducts.   the rest of the world will come to us.. " Ray.. If you build it they will come " 

VACCINE INDUSTRY COLLABORATING TO DEVELOP SOLUTIONS FOR COVID-19
Canada’s Vaccine Industry Committee (VIC) collectively recognizes the responsibility that
we have in working closely with the Government of Canada to safeguard public health and mitigate the impact of COVID-19. The (VIC) is currently engaged with Health Canada and Public Health Agency of Canada to mobilize the full scope of our scientific and manufacturing resources to respond to the current crisis.
 
Our focus is to maintain the current supply of vaccines for all vaccine preventable diseases in Canada. Vaccine Industry Committee members will continue to proudly play their part, and work closely with all levels of government, the research community and public agencies to develop solutions to address our current and future Canadian vaccine supply needs. As an industry, we are committed to dedicating and sharing our scientific expertise, technical skills and manufacturing capabilities to address this unprecedented global health crisis. We are proud to share current examples of our collaborative industry leadership
 
Vaccine Industry Committee Members
Astra Zeneca ; BioteCanada; Biodextris; GSK; IMV; Innovative Medicines Canada; Midicago; Merck; Pfiszer; Plantform; Promis Neurosciences; Red Leaf Medical; Sanofi Pasteur; Seqiras; Smart& Biggar/Fetherstonhaugh; Valneva; VBI; Vido; Vicica

Bullboard Posts